Recent Updates
Recently added Catalysts

LY4247147

Phase 1

Obesity | Small Molecules | Metabolic |Eli Lilly and Company|Trials Updated: Nov 4, 2026

LY4247147 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment108

FDA Designations

No designations recorded

LY4247147 clinical trials

LY4247147 · 1 trial · 2 indications

Phase 1 1
NCT07915245A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise HealthyObesity
NOT YET_RECRUITING108 Analytics
PHASE1NOT YET_RECRUITING
A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Obesity
NCT07915245108
Unlock trial analytics

Study Endpoints

Primary Endpoints

Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through End of the Follow-up (Estimated as Week 25)
Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through End of the Follow-up (Estimated as Week 33)

Secondary Endpoints

Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147
Predose on Day 1 through Week 25
Part B: PK: Cmax of LY4247147
Predose on Day 1 through Week 33
Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147
Predose on Day 1 through Week 25
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LY4247147 Part AEXPERIMENTALLY4247147 administered subcutaneously (SC)
Placebo Part APLACEBO_COMPARATORPlacebo administered SC
LY4247147 Part BEXPERIMENTALLY4247147 administered SC
Placebo Part BPLACEBO_COMPARATORPlacebo administered SC
LY4247147 Part CEXPERIMENTALLY4247147 administered intravenously (IV)

Interventions

NameTypeDescription
LY4247147DRUGadministered SC
PlaceboDRUGadministered SC
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease. * Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²). * Have obesity with a BMI of ≥30...

Countries:United StatesSingapore
Unlock Eligibility Criteria

Competitive Landscape -Obesity 326 trials

Top 20 of 36 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN9PHASE3AZD6234, Elecoglipron, Lenbelintide, AZD9550, AZD1043
Pfizer Inc.PFE18PHASE3Berobenatide, PF-08653945, PF-08656795, PF-08642534
Eli Lilly and CompanyLLY53PHASE3Orforglipron, Tirzepatide, Retatrutide, Eloralintide, Mirikizumab
Amgen Inc.AMGN14PHASE3Maridebart cafraglutide
Novo Nordisk A/S Sponsored ADR Class BNVO73PHASE3Cagrilintide, Semaglutide, Liraglutide, CagriSema, NNC0487-0111
Viking Therapeutics, Inc.VKTX6PHASE3VK2735, VK2735 Drug, VK3019
Regeneron Pharmaceuticals, Inc.REGN5PHASE3mibavademab, Trevogrumab, Garetosmab, Olatorepatide, REGN20934
Rhythm Pharmaceuticals, Inc.RYTM6PHASE3Setmelanotide, RM-718, Bivamelagon
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
Kailera Therapeutics, Inc.KLRA5PHASE3Ribupatide (KAI-9531), KAI-7535
Hoffmann-La RocheRHHBY12PHASE3Enicepatide, Petrelintide, RO7204239, RO7795081
AbbVie, Inc.ABBV2PHASE2ABBV-295
Alnylam Pharmaceuticals, IncALNY2PHASE2ALN-2232, ALN-6222
Structure Therapeutics, Inc. Sponsored ADRGPCR3PHASE3Aleniglipron, ACCG-2671
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE2ARO-INHBE, ARO-ALK7
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
PfizerMTSR1PHASE3MET097
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab
Palatin Technologies, Inc.PTN1PHASE2bremelanotide
Wave Life Sciences Ltd.WVE1PHASE2WVE-007
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWNov 4, 2026NCT07915245NEW_TRIAL: changed
LOWNov 4, 2026NCT07915245NEW_TRIAL: changed

Explore more on BiopharmaWatch

Eli Lilly and Company (LLY)Pipeline, catalysts, financials, insiders and newsObesity disease mapEvery company developing for Obesity, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track